DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer

Background: Preoperative risk stratification is essential in tailoring endometrial cancer treatment, and biomarkers predicting lymph node metastasis and aggressive disease are aspired in clinical practice. DNA ploidy assessment in hysterectomy specimens is a well-established prognostic marker. DNA p...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer Vol. 112; no. 10; pp. 1656 - 1664
Main Authors: Njølstad, T S, Trovik, J, Hveem, T S, Kjæreng, M L, Kildal, W, Pradhan, M, Marcickiewicz, J, Tingulstad, S, Staff, A C, Haugland, H K, Eraker, R, Oddenes, K, Rokne, J A, Tjugum, J, Lode, M S, Amant, F, Werner, H M, Salvesen, H B, Danielsen, H E
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 12-05-2015
Nature Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Preoperative risk stratification is essential in tailoring endometrial cancer treatment, and biomarkers predicting lymph node metastasis and aggressive disease are aspired in clinical practice. DNA ploidy assessment in hysterectomy specimens is a well-established prognostic marker. DNA ploidy assessment in preoperative curettage specimens is less studied, and in particular in relation to the occurrence of lymph node metastasis. Methods: Curettage image cytometry DNA ploidy in relation to established clinicopathological variables and outcome was investigated in 785 endometrial carcinoma patients prospectively included in the MoMaTEC multicentre trial. Results: Diploid curettage status was found in 72.0%, whereas 28.0% were non-diploid. Non-diploid status significantly correlated with traditional aggressive postoperative clinicopathological features, and was an independent predictor of lymph node metastasis among FIGO stage I–III patients in multivariate analysis (OR 1.94, P =0.033). Non-diploid status was related to shorter disease-specific survival (5-year DSS of 74.4% vs 88.8% for diploid curettage, P <0.001). When stratifying by FIGO stage and lymph node status, the prognostic effect remained. However, in multivariate regression analysis, preoperative histological risk classification was a stronger predictor of DSS than DNA ploidy. Conclusions: Non-diploid curettage is significantly associated with aggressive clinicopathological phenotype, lymph node metastasis, and poor survival in endometrial cancer. The prognostic effect was also observed among subgroups with (presumably) less aggressive traits, such as low FIGO stage and negative lymph node status. Our results indicate curettage DNA ploidy as a possible supplement to existing parameters used to tailor surgical treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This study was conducted within ENITEC (European Network for Individualized Treatment of Endometrial Cancer) with the following participating centres in the MoMaTEC (Molecular Markers in Treatment of Endometrial Cancer) trial: Norwegian centres: Haukeland University Hospital, Bergen; St. Olav's Hospital, Trondheim; Oslo University Hospital, Ullevål, Oslo; Akershus University Hospital, Oslo; Haugesund Hospital; Hospital of Vestfold; Førde Hospital; Ålesund Hospital; University Hospital Gasthuisberg Leuven, Belgium; and Sahlgrenska Academy, Sweden.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2015.123